Part3:ABBV-400单药,晚期胃食管腺癌/胃食管交界处腺癌GEA,先前至少接受1线化疗后进展,不超过2线化疗; Part4:ABBV-400单药,未携带BRAF V600E突变和dMMR+/MSI-Hi晚期CRC; Part5:ABBV-400单药,MET扩增,不限癌种; Part6:ABBV-400单药,MET突变,不腺癌...
一项1期试验(NCT05029882)的数据显示,靶向c-Met的新型ADC药物ABBV-400在BRAF野生型、微卫星稳定型(MSS)/错配修复良好型(pMMR)晚期结直肠癌(CRC)患者中显示出初步的抗肿瘤活性,且患者耐受性良好。港安健康国际医疗介绍,ABBV-400将c-Met靶向抗体telisotuzumab与拓扑异构酶1抑制剂有效载荷相结合。c-Met的过表达在...
参考来源: https://www.onclive.com/view/telisotuzumab-adizutecan-represents-a-novel-c-met-targeting-adc-in-met-amplified-crc 编者按 如果您希望了解更多癌症等重大、复杂疾病的海外前沿研究成果、药物、疗法信息,请扫描下方二维码联...
研究方法:试验期间,CRC患者被随机分配接受剂量分别为1.6mg/kg、2.4mg/kg和3.0mg/kgQ3W的ABBV-400。主要终点:ABBV-400的安全性、耐受性、药代动力学初步疗效和推荐的2期剂量。研究结果:截至2023年10月,共纳入122例患者(ESC:29例;EXP:93例),其中ESC患者的随访时间比EXP患者长(14.8个月比3.8个月)。78人(64%...
;12.仅限扩展第 2 部分: -组织学诊断为恶性实体瘤(世界卫生组织 [WHO] 标准)。 -根据 RECIST 1.1 版,存在可测量的疾病。 -受试者患有晚期实体瘤,包括(但不限于)非小细胞肺癌(NSCLC)、头颈部鳞状细胞癌(HNSCC)、胃食管连接部腺癌(GEA)、结肠直肠癌 (CRC)和肾细胞癌(RCC),其在标...
The study is also evaluating ABBV-400 with bevacizumab in pts with CRC.Clinical trial information: NCT05029882.Preliminary efficacy outcomes.CRC Dosing Cohorts1.6 mg/kg Q3W(n = 32)2.4 mg/kg Q3W(n = 40)3.0 mg/kg Q3W(n = 41)Confirmed ORR, n (%)06 (15)8 (20)CBR12, n (%)11 (...
Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD March 9th 2025 The OncFive: Top Oncology Articles for the Week of 3/2 September 12th 2024 Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress March 8th 2025 Nivolu...
Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC.
Preclinically ABBV-400 exhibits favorable pharmacokinetics, anti-proliferative activity in vitro, and compelling efficacy in NSCLC, gastroesophageal, and CRC xenograft models. Furthermore, ABBV-400 is well tolerated by cynomolgus monkeys with bone marrow and gastrointestinal tract toxicities common to other...
c-Met overexpression frequently occurs in a variety of tumors, including CRC. ABBV-400 is a c-Met–directed antibody-drug conjugate composed of the monoclonal antibody telisotuzumab conjugated to a potent topoisomerase 1 inhibitor payload. Preliminary data from the first-in-human study of ABBV-...